Affibody to reveal data from first-in-human cancer trial
First-in-human data from a study into a radioligand therapy (RLT) targeting metastatic breast cancer is set to be announced.
Radiopharmaceutical company Affibody will present the data on ABY-271, the HER2-targeting RLT candidate, at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting. The event will take place 30 May – 2 June in Los Angeles, US.
The Phase I study is a first-in-human, open-label, randomised trial to assess the safety, tolerability, and biodistribution of ABY-271 in tumours and critical organs in subjects with HER2-positive metastatic breast cancer.
The study consists of two parts: Part A, in which the uptake of ABY-271 in tumours and critical organs has been evaluated in two patients, and Part B, in which higher radioactivity levels and additional protein mass doses will be evaluated in 15 patients.
Affibody previously announced data from the completed Part A, which demonstrated tumour targeting and a favourable safety profile with low uptake in kidneys and other critical organs consistent with preclinical predictions.
“We are pleased to present encouraging first-in-human data for our lead RLT candidate ABY-271 at SNMMI, one of the world-leading scientific events in nuclear medicine and molecular imaging,” said David Bejker, CEO of Affibody.
“These initial clinical results mark a significant milestone for our RLT pipeline, and we are honoured that it has been selected for Poster Oral Presentation, reflecting the strong scientific interest in innovative approaches to treat HER2-positive metastatic breast cancer.”
